123 related articles for article (PubMed ID: 37443750)
1. TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity.
Kaminski MF; Bendzick L; Hopps R; Kauffman M; Kodal B; Soignier Y; Hinderlie P; Walker JT; Lenvik TR; Geller MA; Miller JS; Felices M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162918
[TBL] [Abstract][Full Text] [Related]
2. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
[TBL] [Abstract][Full Text] [Related]
3. Tri-specific killer engager: unleashing multi-synergic power against cancer.
Winidmanokul P; Panya A; Okada S
Explor Target Antitumor Ther; 2024; 5(2):432-448. PubMed ID: 38745768
[TBL] [Abstract][Full Text] [Related]
4. cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor [alpha]2 chain.
Yu W; Su Z; Wu Z; Mao X; Zheng W; Zeng Y
Cancer Immunol Immunother; 2009 Mar; 58(3):409-13. PubMed ID: 18677476
[TBL] [Abstract][Full Text] [Related]
5. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
Kringel R; Lamszus K; Mohme M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
[TBL] [Abstract][Full Text] [Related]
7. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
8. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
9. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L; Mohanty V; Dou J; Huang Y; Banerjee PP; Miao Q; Lohr JG; Vijaykumar T; Frede J; Knoechel B; Muniz-Feliciano L; Laskowski TJ; Liang S; Moyes JS; Nandivada V; Basar R; Kaplan M; Daher M; Liu E; Li Y; Acharya S; Lin P; Shanley M; Rafei H; Marin D; Mielke S; Champlin RE; Shpall EJ; Chen K; Rezvani K
Sci Adv; 2023 Jul; 9(30):eadd6997. PubMed ID: 37494448
[TBL] [Abstract][Full Text] [Related]
10.
Carannante V; Wiklund M; Önfelt B
Front Immunol; 2023; 14():1135148. PubMed ID: 37457703
[TBL] [Abstract][Full Text] [Related]
11. Can't drop the MIC(A/B): Preventing stress-ligand shedding to enhance pan-cancer targeting.
Lakes N; Canaday LM; Waggoner SN
Med; 2023 Jul; 4(7):398-400. PubMed ID: 37453414
[TBL] [Abstract][Full Text] [Related]
12. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and extrinsic factors determining natural killer cell fate: Phenotype and function.
Zhi L; Wang X; Gao Q; He W; Shang C; Guo C; Niu Z; Zhu W; Zhang X
Biomed Pharmacother; 2023 Sep; 165():115136. PubMed ID: 37453199
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma stem cell metabolism and immunity.
Hawly J; Murcar MG; Schcolnik-Cabrera A; Issa ME
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38530545
[TBL] [Abstract][Full Text] [Related]
15. Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas.
Li X; Xiao X; Wang Y; Gu G; Li T; Wang Y; Li C; Zhang P; Ji N; Zhang Y; Zhang L
Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201655
[TBL] [Abstract][Full Text] [Related]
16. Harnessing immune cells to eliminate HIV reservoirs.
Grasberger P; Sondrini AR; Clayton KL
Curr Opin HIV AIDS; 2024 Mar; 19(2):62-68. PubMed ID: 38167784
[TBL] [Abstract][Full Text] [Related]
17. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas.
Pawlowski KD; Duffy JT; Tiwari A; Zannikou M; Balyasnikova IV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443750
[TBL] [Abstract][Full Text] [Related]
18. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
